7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/17/2013

Company Name Symbol %Change
VIASAT INC VSAT
19.35%
OLD SECOND B OSBC
5.76%
GAMCO INVEST GBL
4.61%
CORNING INC GLW
4.47%
SYNCHRONOSS SNCR
4.23%

Rite Aid's Comps Improved

by Zacks Equity Research

August 03, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Drugstore chain retailer Rite Aid Corporation’s ( RAD - Analyst Report ) same-store sales (comps) reported an increase of 0.5% for the four-week period ended July 28, 2012. The improvement was driven by positive front-end, pharmacy and prescription count comps for the month.

Front-end same-store sales for July 2012 marginally increased 1.2%, while pharmacy comps inched up 0.2%. Prescription count at comparable stores witnessed an upside of 4.5%. Pharmacy comps for July included a negative impact of around 742 basis points from new generic introductions.

Rite Aid reported total drugstore sales of $1.881 billion in the month under review, with prescription sales accounting for 67.5% of drugstore sales and third-party prescription sales making up for 96.4% of pharmacy sales. The company’s July sales represented a 0.1% dip from the year-ago level of $1.883 billion.

For the 21-week period ended July 28, 2012, Rite Aid registered a comps increase of 1.5%. Comps for the period comprised a 2% rise in front-end comps and a 1.2% hike in pharmacy comps. Prescription count at comparable stores grew 3.2% during the period.

Total drugstore sales of $10.247 billion for the 21-week period reflected a 0.8% increase from $10.167 billion reported in the year-ago period. Sales for the 21-week period included a 68.1% contribution from prescription sales with third-party prescription sales making up for 96.6% of pharmacy sales.

Our Recommendation

In an effort to expand its pharmacy and clinical services, Rite Aid has applied additional resources, such as the Wellness+ program for diabetes and Flu Immunization. We believe such programs will enable the company to increase its customer base as well as long-term profitability.

Moreover, the company is taking various cost-cutting initiatives, such as centralized indirect procurement of drugs, managing administrative headcounts, reducing supply chain costs, reducing debt, etc., which should help improve the bottom line.

Headquartered in Camp Hill, Pennsylvania, Rite Aid is the third-largest retail drugstore in the U.S. on the basis of revenues and number of stores. The company operates in 31 states across the country and in the District of Columbia. As of July 28, 2012, the company operated 4,646 stores as compared with 4,702 stores in the same period last year.

Rite Aid competes with CVS Caremark Corporation ( CVS - Analyst Report ) and Walgreen Co. ( WAG - Analyst Report ) . Currently, the company has a Zacks #3 Rank, implying a short-term Hold rating. Moreover, we are maintaining a long-term Neutral recommendation on the stock.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.